The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial
Abstract
The efficacy and tolerance of the nonsteroidal antiandrogen nilutamide in the treatment of prostatic cancer were studied in a large double-blind clinical trial initiated in 1986. Patients with metastatic prostatic cancer without prior endocrine manipulation underwent orchiectomy and were randomized to 1 of 2 groups receiving nilutamide (225 patients) or placebo (232). Nilutamide and placebo were evaluated for efficacy in 207 and 216 patients, respectively. Progression-free survival was significantly longer in the nilutamide group (median time to progression 20.8 months on nilutamide and 14.9 months on placebo, p = 0.005). Median time to death from prostatic cancer was 30.0 months in the placebo group and 37 months in the nilutamide group. Objective regressions were higher in the nilutamide group (41%) than in the placebo group (24%). Significant differences in favor of the nilutamide group were found at several intervals for bone pain, prostatic acid phosphatase, prostate specific antigen, alkaline phosphatase and bone scan isotope uptake. Nilutamide and orchiectomy constitute a more effective treatment for metastatic prostatic cancer than orchiectomy alone, and the adverse effects of nilutamide, usually minor, are outweighed by the significant improvements in most disease measures and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Cited by
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Self-citationIs dehydroepiandrosterone a hormone?
Labrie, F., Luu-The, V, Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., & Labrie, C. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06264 · Cited by 451
Roy, A. K., Lavrovsky, Y., Song, C. S., Chen, S., Jung, M. H., Velu, N. K., Bi, B. Y., & Chatterjee, B. (1998) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60938-3 · Cited by 411
Androgen deprivation therapy for prostate cancer: Current status and future prospects
Miyamoto, H., Messing, E. M., & Chang, C. (2004) · The Prostate · doi:10.1002/pros.20115 · Cited by 317
Management of Cancer of the Prostate
Wood, A. J. J., & Catalona, W. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311507 · Cited by 294
Metadata
- Authors
- Janknegt, R. A., Abbou, C. C., Bartoletti, R., Bernstein-Hahn, L., Bracken, B., Brisset, J. M., Calais Da Silva, F., Chisholm, G., Crawford, E. D., Debruyne, F. M. J., Dijkman, G. D., Frick, J., Goedhals, J., Knönagel, H., & Venner, P. M.
- Venue
- Journal of Urology
- Published
- 1993-01
- Volume
- 149
- Issue
- 1
- Pages
- 77-82
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W116367892
- Cited by
- 181
- References
- 1
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial. https://app.cochat.ai/papers/10.1016/s0022-5347(17)36003-2
- The paper
- Janknegt, R. A., Abbou, C. C., Bartoletti, R., Bernstein-Hahn, L., Bracken, B., Brisset, J. M., Calais Da Silva, F., Chisholm, G., Crawford, E. D., Debruyne, F. M. J., Dijkman, G. D., Frick, J., Goedhals, J., Knönagel, H., & Venner, P. M. (1993). Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial. Journal of Urology. https://doi.org/10.1016/s0022-5347(17)36003-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
